In addition, it has been reported that PD-L1 is preferentially expressed on macrophages rather than cancer cells (56), and in the mice model, TAMs can reduce the anti-cancer immune response of CD8+ and CD4+ T cells by expressing PD-L1 (57). Here, CD8A is linked to cancer.